Global Dementia - Alzheimer Disease Market, By Drug Class (Cholinergic/Cholinesterase (ChE) Inhibitors, Memantine, and Combined Drug), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales) - Industry Trends and Forecast to 2030.
Dementia - Alzheimer Disease Market Analysis and Size
Dementia is not a normal part of aging. It is caused by damage to brain cells that affects their ability to communicate, which can affect thinking, behaviour, and feelings. The primary factor is bolstering the market's growth for the rapid development of the obese population due to sedentary lifestyles and unhealthy dietary patterns. With the rising obesity rates and other metabolic disorders, there has been an increase in awareness among individuals about the importance of health and wellness.
Data Bridge Market Research analyses that the market, which was USD 13,000.00 million in 2022, would rocket up to USD 25,000.00 million by 2030 and is expected to undergo a CAGR of 8.5% during the forecast period. Cholinergic/Cholinesterase (ChE) inhibitors dominate the drug class segment of the Dementia - Alzheimer Disease market owing to the growing demand for chronic diseases. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dementia - Alzheimer Disease Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015-2020)
Revenue in USD Million, Volumes in Units, and Pricing in USD
By Drug Class (Cholinergic/Cholinesterase (ChE) Inhibitors, Memantine, and Combined Drug), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales)
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America
Market Players Covered
Merz Pharma GmbH & Co. KGaA (U.S), Novartis AG (Switzerland), Pfizer, Inc (U.S)., Ono Pharmaceutical Co., Ltd. (U.S), Johnson & Johnson Services, Inc (U.S), H. Lundbeck A/S (Denmark), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc.(U.S), Eli Lilly and Company (U.S), and Corium, Inc (U.S) among others
Dementia is a general term for a decline in mental ability severe enough to interfere with daily life, while alzheimer's is a specific disease. It is the most common cause of dementia. Dementia describes symptoms associated with decreased memory, reasoning, or other thinking skills. Many different types of dementia exist, and many conditions cause it. Mixed dementia is a condition in which brain changes of more than one type of dementia coincide. Alzheimer's disease is the most common cause of dementia, accounting for 60-80% of dementia cases.
Global Dementia - Alzheimer Disease Market Dynamics
- Rising number of obese patients
A growing number of obese patients is directly influencing the demand for body composition analyzers.
The growing prevalence of obesity among adults and children can be credited to factors including sedentary lifestyles, hypertension, high blood lipids, and diabetes mellitus. These incidents and rising awareness about healthy lifestyles are expected to provide a significant impetus to the global market for body composition analyzers.
- Research and development proficiencies
Rising expenditure for research and development proficiencies, especially in developed and developing economies about medical instruments and devices, will further create lucrative market growth opportunities. Research and development proficiencies being conducted to grow medical devices are also expected to drive market growth.
- Growing investment in healthcare facilities
Surging focus on improving healthcare facilities' condition and overall healthcare infrastructure is another essential factor fostering the market growth. The rising number of partnerships and strategic collaborations between the public and private players about funding and application of new and improved technology is further expected to create lucrative market opportunities.
Furthermore, an upsurge in the public-private funding for target research activities, rising demand for chronic disease treatment, and rising product innovations and development owing to technological advancements worldwide will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising internet penetration rate, rise in the elderly and obese population globally, and increasing per capita expenditure on health care will further expand the market's growth.
- The absence of awareness in backward economies
On the other hand, high costs associated with research and development proficiencies, limited infrastructural facilities, and a shortage of awareness in backward economies are expected to obstruct market growth. Also, the lack of favorable reimbursement scenarios and technology penetration in developing economies, the heavy customs duty imposed on medical devices, and the lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Dementia - Alzheimer Disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
- In January 2022, a new initiative by McGill University’s Dementia Education Program received funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities
- In September 2022, Corium, Inc launched ADLARITY (donepezil transdermal system) for Patients with alzheimer's dementia. The company stated that this would be available for prescription in the U.S. for the treatment of patients with mild, moderate, or severe dementia of the alzheimer's type.
Global Dementia - Alzheimer Disease Market Scope
The market is segmented on the basis of drug class and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Cholinergic/Cholinesterase (ChE) Inhibitors
- Combination Drugs
- Hospital Pharmacy
- Retail Pharmacy
- Online Sales
Global Dementia - Alzheimer Disease Market Regional Analysis/Insights
The market is analysed, and market size insights and trends are provided by country, drug class, and distribution channel as referenced above.
The countries covered in the Dementia - Alzheimer Disease market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
North America is expected to dominate the market because of the strong base of healthcare facilities, the strong presence of major players in the market, increased cases of chronic diseases, and the rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Dementia - Alzheimer Disease market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Dementia - Alzheimer Disease market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Dementia - Alzheimer Disease market. The data is available for the historic period 2010-2020.
Competitive Landscape and Dementia - Alzheimer Disease Market Share Analysis
The Dementia - Alzheimer Disease market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Dementia - Alzheimer Disease market.
Some of the major players operating in the Dementia - Alzheimer Disease market are:
- Merz Pharma GmbH & Co. KGaA (U.S)
- Novartis AG (Switzerland)
- Pfizer, Inc (U.S)
- Ono Pharmaceutical Co., Ltd. (U.S)
- Johnson & Johnson Services, Inc (U.S)
- H. Lundbeck A/S (Denmark)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- AbbVie Inc.(U.S)
- Eli Lilly and Company (U.S)
- Corium, Inc (U.S)